As of 2026-07-15, the Intrinsic Value of Zentalis Pharmaceuticals Inc (ZNTL) is -12.20 USD. This ZNTL valuation is based on the model Peter Lynch Fair Value. With the current market price of 4.77 USD, the upside of Zentalis Pharmaceuticals Inc is -355.71%.
Based on its market price of 4.77 USD and our intrinsic valuation, Zentalis Pharmaceuticals Inc (ZNTL) is overvalued by 355.71%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -12.20 - -12.20 | -12.20 | -355.71% |
| P/E | (41.72) - (49.62) | (45.13) | -1046.1% |
| DDM - Stable | (19.62) - (105.55) | (62.58) | -1412.0% |
| DDM - Multi | (0.43) - (1.79) | (0.69) | -114.5% |
| Market Cap (mil) | 268.00 |
| Beta | 2.22 |
| Outstanding shares (mil) | 56.18 |
| Enterprise Value (mil) | 236.07 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.39% |
| Cost of Debt | 5.00% |
| WACC | 7.19% |